FAQ: Quantum BioPharma's Licensee Unbuzzd Wellness Investor Webinar and Business Relationship
Summary
Quantum BioPharma's licensee Unbuzzd Wellness is hosting an investor webinar on October 30, 2025, as part of its $5 million fundraising effort for unbuzzd™, a scientifically proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. This event is significant as it represents a non-dilutive funding opportunity for Quantum shareholders and showcases the commercial development of Quantum's intellectual property.
What is the main announcement in this content?
Quantum BioPharma’s licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, at 4:15 p.m. ET as part of its Reg D 506(c) offering and up to $5 million raise, which involves no dilution to Quantum shareholders.
Who will be participating in the investor webinar?
The webinar will feature Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius, who will discuss the investment opportunity and company strategy.
What is unbuzzd™ and what does it do?
unbuzzd™ is a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms, developed from Quantum BioPharma’s intellectual property.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness?
Quantum BioPharma invented unbuzzd™ and spun out its OTC version to Unbuzzd Wellness, retaining 20.11% ownership (as of March 31, 2025) and receiving 7% royalty payments on sales until $250 million is reached, then 3% in perpetuity.
Why is this webinar important for Quantum BioPharma shareholders?
The $5 million fundraising by Unbuzzd Wellness involves no dilution to Quantum shareholders, and successful development of unbuzzd™ could generate significant royalty revenue for Quantum BioPharma through the agreed payment structure.
What are Quantum BioPharma’s main areas of focus beyond unbuzzd™?
Quantum BioPharma focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with lead compound Lucid-MS for multiple sclerosis, and maintains strategic investments through its FSD Strategic Investments subsidiary.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/yX7kt.
What rights does Quantum BioPharma retain for pharmaceutical development?
Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, separate from the OTC version licensed to Unbuzzd Wellness.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 262723